Pancrelipase (amylase;lipase;protease) Patent Expiration
Pancrelipase (Amylase;Lipase;Protease) is Used for managing symptoms of exocrine pancreatic insufficiency in patients with cystic fibrosis or other conditions. It was first introduced by Organon Usa Inc
Pancrelipase (amylase;lipase;protease) Patents
Given below is the list of patents protecting Pancrelipase (amylase;lipase;protease), along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Creon | US9198871 | Delayed release pancreatin compositions | Feb 07, 2030 | Abbvie |
| Pancreaze | US8221747 | Stable pancreatic enzyme compositions | Feb 20, 2028 | Vivus Inc |
| Pancreaze | US8562978 | Stable digestive enzyme compositions | Feb 20, 2028 | Vivus Inc |
| Pancreaze | US8562979 | Stable digestive enzyme compositions | Feb 20, 2028 | Vivus Inc |
| Pancreaze | US8562980 | Stable digestive enzyme compositions | Feb 20, 2028 | Vivus Inc |
| Pancreaze | US8562981 | Stable digestive enzyme compositions | Feb 20, 2028 | Vivus Inc |
| Zenpep | US7658918 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8221747 | Stable pancreatic enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8221747 | Stable pancreatic enzyme compositions | Feb 20, 2028 | Zenpep |
| Zenpep | US8246950 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8562978 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8562978 | Stable digestive enzyme compositions | Feb 20, 2028 | Zenpep |
| Zenpep | US8562979 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8562979 | Stable digestive enzyme compositions | Feb 20, 2028 | Zenpep |
| Zenpep | US8562980 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8562980 | Stable digestive enzyme compositions | Feb 20, 2028 | Zenpep |
| Zenpep | US8562981 | Stable digestive enzyme compositions | Feb 20, 2028 | Aptalis Pharma Us |
| Zenpep | US8562981 | Stable digestive enzyme compositions | Feb 20, 2028 | Zenpep |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pancrelipase (amylase;lipase;protease)'s patents.
Latest Legal Activities on Pancrelipase (amylase;lipase;protease)'s Patents
Given below is the list recent legal activities going on the following patents of Pancrelipase (amylase;lipase;protease).
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8246950 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jul, 2021 | US7658918 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2020 | US8246950 |
| Email Notification Critical | 29 Sep, 2014 | US8246950 |
| Change in Power of Attorney (May Include Associate POA) Critical | 29 Sep, 2014 | US8246950 |
| Change in Power of Attorney (May Include Associate POA) Critical | 26 Sep, 2014 | US7658918 |
| Email Notification Critical | 26 Sep, 2014 | US7658918 |
| Correspondence Address Change Critical | 24 Sep, 2014 | US7658918 |
| Correspondence Address Change Critical | 24 Sep, 2014 | US8246950 |
| Mail Pre-Exam Notice | 05 Aug, 2014 | US7658918 |
Pancrelipase (amylase;lipase;protease)'s Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pancrelipase (amylase;lipase;protease):
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Pancrelipase (amylase;lipase;protease) has 1 clinical trial that has been verified in 2024.